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Abstract  
Introduction: Second malignancy could be either previous therapy related or non-therapy related like syndromic or 
shared etiologic exposure. It could be either a hematological/solid malignancy following tretment for previous solid 
tumour or prior hematological malignanacy.Review of literature regarding secondary Chronic Myeloid Leukemia (CML) 
following previous active treatment for primary cancer is listed out for further understanding. 
Presentation of Case: We describe a 71 year old elderly male who developed Chronic Myeloid Leukemia(CML) after a 
period of 6 years during follow up of Stage IV Diffuse Large B-Cell Lymphoma(DLBCL) for which he received 8 cycles 
of R-CHOP based Chemo-immunotherapy in 2008 .Whether it is therapy related Chronic Myeloid Leukemia (trCML) 
following prior cytotoxic treatment or simply a non-therapy related second malignancy hronic Myeloid 
Leukemia(smCML) is a matter of debate.However our patient responded dramatically like denova CML to imatinib 
therapy. 
Conclusion: Therapy related CML or non therapy related second malignancy CML following DLBCL treatment is rare 
but responds dramatically like denova CML to imatinib therapy. 
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Introduction 
Second malignancy could be either previous therapy related or non-therapy related like syndromic or 
shared etiologic exposure. It could be either a hematological/solid malignancy following treatment for 
previous solid tumour or prior hematological malignanacy. Review of literature regarding secondary 
Chronic Myeloid Leukemia (CML) following previous active treatment for primary cancer is listed 
out for further understanding. 
Case Presentation 
Seventy one year old male was diagnosed with Diffuse Large B-Cell Lymphoma(DLBCL,Stage IV A ) 
in 2008 (Figure 1)and subsequently treated with 8 cycles of R CHOP . He attained complete metabolic 
remission and was on regular follow up on outpatient basis. He was completely asymptomatic and his 
Total leukocyte count(TLC) rose from 18,000/cumm in May 2014 to 87,400/cumm in Aug 2014. The 
Peripheral smear(Figure 2) showed marked leucocytosis with shift to left with preponderance of 
myeloid precursors with peak in neutrophil lineage with basophilia (DLC : My-21, MMy-11, N-51,L-
05,M-03, E-04,B-05) . A Bone marrow aspirate and Bone marrow biopsy examination along with 
testing for Bcr/Abl rearrangement was advised. However, he defaulted briefy and returned again with 
weakness & easy fatiguability and TLC of 2,15,700/cumm in may 2015 with a Differential Count as 
follows (DLC-Bl-02, My-40, MMy-12,N-40, L-02, M-01, E-01, B-02). Clinical examination revealed 
no palpable lymphadenopathy or hepatosplenomegaly. RT-PCR for Bcr/Abl rearrangement was done 
and was positive (Figure 3) . CT scan evaluation showed no evidence of lymphoma involvement. A 
diagnosis of therapy related Chronic Myeloid Leukemia (trCML) or non-therapy related second 
malignancy Chronic Myeloid Leukemia (smCML) following DLBCL has been made and started on 
Imatinib 400 mg once daily with adequate hydration and tumour lysis prophylaxis. He improved 
dramatically and his last TLC count after one month of imatinib therapy has reduced to 24,000 with 
marked improvement in weakness and fatigue. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Biopsy of Lymph node showing large monomorphic cells with prominent nucleoli suggestive of 
Diffuse Large Cell Lymphoma (400X) 
  
 
Page 3 of 9 
Louis R et al. American Journal of Cancer Case Reports 2016, 4:1-9 
6 
Ivy Union Publishing | http: //www.ivyunion.org April 11, 2016 | Volume 4, Issue 1 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Peripheral smear picture showing left shift in myeloid series with basophils suggestive of Chronic 
Myeloid Leukemia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Agarose Gel Detection of Bcr/Abl :Lane1- normal control, Lane 3 patient – Mbcr, Lane 4, 5 - +ve 
control, Lane 6 – 100bp molecular ladder, E1a2 – 381bp, E13a2 – 285bp, E14a2 – 360bp 
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Discussion 
Non-Hodgkins Lymphoma(NHL) patients have a significant increased risk of developing second 
primary cancers. Second malignancy following non-Hodgkins lymphoma(NHL) therapy can be either 
therapy related or non-therapy related. Therapy related factors include previous 
chemotherapy(Topisomerase inhibitors, alkylationg agents etc), Radiation therapy or combined 
modality treatment. Factors such as better survival following previous effective treatment, increasing 
age, genetic susceptibility, viral infections, tobacco use or immunolgic alteration are possible reasons 
for non-therapy related second malignancy[1-3]. The risk of second cancer after NHL increases as 
much as 47% and the incidence ratio increases with age with the cumlulative incidence of 8.2% at 15 
years [4,5]. The pooled Relative Risk of second malignant neoplasms after NHL therapy is increased 
than general population and the risk impact differs for various treatment modalities [6]. Therapy 
related second primary cancer increases with every decade since NHL diagnosis with relatively excess 
risk observed in older patients [7,8]. The pattern of second malignancy differs by NHL subtype. Both 
hematological and solid malignancy has been documented after NHL therapy. Treatment related 
malignancy following NHL therapy include cancer of lung, bladder, stomach, myeloid leukemia and 
hodgkins lymphoma. While the Standardised Incidenced Ratio(SIR) of acute non-lymphocytic 
leukemia(SIR 4.96 & 5.96) is increased enormously after Diffuse large B Cell Lymphoma (DLBCL) 
and Follicular Lymphoma(FL) treatment, Chronic Myeloid Leukemia(SIR 2.5 vs 0.9 & 1.75) risk is 
elevated after DLBCL as compared with Chronic Lymphocytic Leukemia/Small Lymphocytic 
Leukemia and Follicular Lymphoma treatment(P < 0.5 ) [9]. Around 150 cases of therapy related or 
second malignancy CML has been described in literature post treatment of solid or Lymphoid 
malignancies(Table 1).The median duration in development of trCML is 4 years(range 5 months to 14 
years).Therapy related CML has been described after the receipt of chemotherapy or Radiotherapy 
alone or after combined modality treatment.Prior therapy for hematolymphoid malignancies for low 
grade NHL (like CLL, follicular lymphoma, waldenstroms macroglobulinemia) and high grade 
NHL(like DLBCL) included treatment with chlorambucil to Rituximab based immunochemotherapy 
with or without Radiotherapy [10-26]. Therapy for solid tumours with histologic specific 
chemotherapy schedules (including oxaliplatin, irinotecan, 5Flurouracil based therapy for colorectal 
cancer[27-31] and anthracyclin based chemotherapy for breast cancer) and Radiation therapy for solid 
tumours (like cancer cervix, breast cancer, rectal cancer) [32-35] as a part of multimodality treatment 
has caused trCML. Radioactive therapy with 131I for thyroid cancer has also been implicated in 
therapy related CML [36-38]. Recently more cases of treatment related CML has been noted after 
using S1 chemotherapy especially when given for prolonged time(typically 1 or 2 yrs) as in Japan 
where S1 is being used increasingly in many solid tumours in adjuvant or metastatic setting [39-44]. 
Two patient had unusual synchronus presentation of CML with Gastrointestinal Stromal tumour 
diagnosis which has been treated with imatinib, the standard treatment for both the condition with 
good outcome [45]. Treatment related CML or non therapy related second malignant CML cannot be 
distinguished from denova CML cytogenitically. Treatment related CML is more increasingly 
recognised than non-therapy related second malignant CML because of increasingly aggressive 
therapy for primary malignancy although there is no better objective way to identify the nature of them. 
Non therapy related Second malignant CML tend to increase with increasing age at onset of first 
primary and is a rare entity [13,14]. However both therapy related or non-therapy related CML 
respond favourably to imatinib therapy and behave similar to denova CML [21,22]. 
Secondary CML following DLBCL has been reported recently in 4 case reports where it was noted 
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to occur from 9 months to 10 year post DLBCL treatment with CHOP based chemotherapy plus or 
minus rituximab /Radiotherapy [10,12,15,19]. One case diagnosed CML synchronously with NHL 
relapse which was treated with combination of rituximab and Imatinib [18]. 
 
Table 1 Table showing published Case reports/Series of therapy related or second malignancy CML following 
treatment of primary hematolymphoid or solid tumours. 
 
Author Primary Cancer Treatment Number of 
patients 
Duration 
since 
primary 
treatment 
Reference 
Demiriz IŞ DLBCL R CHOP 1 5 years 10 
Shibazaki M Folicular Lymphoma Chemotherapy(RFM Protocol) 1 3 years 11 
Lee HY DLBCL Chemotherapy(CHOP)+Radiation 1 10 years 12 
Aguiar RC  Both solid and hematologial(5 
CLL,2 NHL) 
Chemotherapy 32 - 13 
Specchia G Both solid and hematologial - 9+77(therapy 
related) 
- 14 
Zahra K DLBCL in a child Chemotherapy 1 9 months 15 
Alsop S ALK +ALCL Chemotherapy 1 4 years 16 
Bolaños-Meade Lymphoid Chemotherapy 1 7 years 17 
Breccia M NHL chemotherapy 1 - 18 
Hsiao HH Lymphoma(High grade 
MALT) 
Chemotherapy+PBSCT 1 10 months 19 
Wandroo FA Hairy cell leukemia deoxycoformycin 1 4 years 20 
Ramanarayanan 
J 
Lymphoid 
malignancies(HL,NHL,CLL) 
Chemotherapy 3 8,10,2.5 
years 
respectively 
21 
Waldman D NHL,Nasopharynx Chemotherapy,Radiation 2 - 22 
Verhoef GE Hodgkins lymphoma Chemotherapy 1 8 years 23 
Cazzola M NHL Chemotherapy+Radiotherapy 1 - 24 
Ragupathi L Multiple myeloma Steroids  1 1.5 years 25 
Majado MJ Waldenstrms 
macroglobulinemia 
Chlorambucil 1 3 years 26 
Gokel Y Colon adenocarcinoma Chemotherapy(cisplatin+5FU) 1 - 27 
Vakili-Sadeghi 
M 
Rectosigmoid Oxaliplatin  
+5FU 
1 2 years 28 
Kadikoylu G Rectal adenocarcinoma Chemotherapy(Oxaliplatin,5 1 3 years 29 
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FU,Irinotecan) 
Buxhofer-Ausch 
V 
Metastatic colorectal cancer Chemotherapy(FOLFIRI +Cetuximab) 1 1 year 30 
Manabe M Rectal cancer S1 therapy(1 year) 1 3 years 31 
Pavithran K Papillary thyroid caner Radioactive iodine 131 1 14 years 32 
Wang KL Papillary thyroid cancer Radioactive iodine 131 1 13 years 33 
Walgraeve D Thyroid cancer Radioactive iodine 131 1 - 34 
Shimon I Papillary & Follicular Radioactive iodine 131 2 4 & 10 years 35 
Porta C Breast cancer Chemotherapy 1 - 36 
Bauduer F Breast,cervix Radiotherapy 3 1-25 years 37 
Abu-Ghanem S Breast cancer Chemotherapy 2 1 year 38 
Tsuzuki M Gastric cancer 5'-deoxy-5-fluorouridine 1 6 years 39 
Higuchi M Gastric cancer T –S1 therapy(21 months) 1 3 years 40 
Waller CF Small cell lung cancer High dose 
chemotherapy+autoSCT+Radiotherapy 
1 2 years 41 
Noda M Pineal germinoma Chemotherapy+Radiation 1 4 years 42 
      
Numata A Ewings sarcoma Autologous stem cell transplant 1 4 years 43 
Langabeer SE Prostate cancer Radiotherapy 1 5 months 
post RT 
44 
Sakamoto E GIST Imatinib 2 synchronus 45 
Present Case DLBCL R-CHOP 1 6 years - 
Conclusion 
In our patient, the secondary CML is believed to be either treatment related or non therapy related. The 
fact he has received prior rituximab and anthracycline based therapy and no clinically palpable or 
enlarged splenomegaly by imaging may point to therapy related CML. The older age at onset of 
primary NHL and development of CML after 6 years of follow up may indicate non therapy related 
secondary CML, although such factors and other unknown factors in play cannot be identified 
clinically to distinguish accurately between the two. Therapy related CML or non therapy related 
second malignancy CML following DLBCL treatment is rare but responds dramatically like denova 
CML to imatinib therapy. 
Consent 
We conform Informed written consent from the patient has been obtained for the purpose f publication 
of case report. 
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